ALIOF News Alert Actelion Ltd (ALIOF) 117.5100 09/19/2014 21

New Post Public Reply Private Reply Replies (0) Message Board

Sep 19, 2014 at 10:33 PM

Actelion Ltd (ALIOF) 117.5100 $ALIOF

Acute Inflammation Therapeutics Pipeline Report 2014 - 9 Companies & 10 Drug Profiles
M2 - Wed Sep 10, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/849tzx/acute) has announced the addition of the "Acute Inflammation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Inflammation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioLineRx, Ltd. - Actelion Ltd - Forest Laboratories, Inc. - Italfarmaco S.p.A. - Alligator Bioscience AB - Anacor Pharmaceuticals, Inc. - Omeros Corporation - Dompe Farmaceutici S.p.A. - Peptinnovate Limited Drug Profiles - ACT-389949 - ATL-1222 - CGEN-856 - ADC-1004 - DF-2156A - Selective Inhibitor of Pro Inflammatory Cytokine - AN-3485 - PIN-201104 - Small Molecule Targeting GPR32 for Acute Inflammation - Distamycin Derivatives For more information visit http://www.researchandmarkets.com/research/849tzx/acute

Ligand Up on Multi-Program Captisol Deal with Avion Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 4:10PM CDT
Ligand Pharmaceuticals Incorporated (LGND) entered into a deal with Avion Pharmaceuticals, LLC, under which four Captisol-enabled programs will be developed and commercialized.

Achillion Pharmaceuticals Soars on Mid-Stage HCV Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 3:45PM CDT
Achillion Pharmaceuticals (ACHN) reported positive interim results from a phase II study on ACH-3102.

Gilead Scores Legal Victory Over Roche for Sovaldi, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 12:34PM CDT
Gilead (GILD) received a favorable verdict on Sovaldi.

TrovaGene (TROV) Worth Watching: Stock Rises 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 8:39AM CDT
TrovaGene, Inc. (TROV) was a big mover last session, as its shares rose almost 9% on the day.

NewLink Genetics Corp. (NLNK) Jumps: Stock Adds 8.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 7:51AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as its shares rose almost 9% on the day.

Achillion Pharmaceuticals (ACHN) in Focus: Stock Up 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 7:44AM CDT
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares gain nearly 10% on the day.

Epizyme (EPZM) Crumbles: Stock Falls by 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 7:33AM CDT
Epizyme has been witnessing a flat movement in its earnings estimate front and its share price has been declining for past 24 hours

Amgen's FOCUS Study on Multiple Myeloma Drug Kyprolis Fails - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 4:20PM CDT
Amgen (AMGN) suffered a major setback when its phase III study, FOCUS on multiple myeloma treatment, Kyprolis did not meet its primary endpoint.

Genomic Health Raised to Buy on Better-than-Expected Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 11:10AM CDT
Genomic Health's (GHDX) sales grossed $70.5 million, up 10.7% year over year, exceeding the Zacks Consensus Estimate of $69 million

Halozyme Gains on Narrower-than-Expected Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:53AM CDT
The company's second quarter 2014 loss came in at 13 cents per share, narrower than the year-ago loss of 20 cents per share and the Zacks Consensus Estimate of a loss of 18 cents per share.

Insmed Incorporated (INSM) in Focus: Stock Up 10.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 8:39AM CDT
Insmed Incorporated (INSM) was a big mover last session, as its shares rose nearly 11% on the day.

InterMune (ITMN) Jumps: Stock Adds 14.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 7:51AM CDT
InterMune, Inc. (ITMN) was a big mover last session, as its shares rose over 14% on the day.

Dendreon Down on Default Risk, Reports Narrower Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 1:37PM CDT
Shares of Dendreon Corporation (DNDN) were down significantly after the company warned that it will not be able to repay or refinance its notes due 2016.

BioDelivery Sciences Q2 Loss Narrows, Up on Solid Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 12:02PM CDT
Shares of BioDelivery Sciences International, Inc. (BDSI) jumped 7.58 % after the company reported its second-quarter 2014 results.

Myriad Genetics' Q4 Earnings Beat Estimates, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 8:40AM CDT
In the fourth quarter, Myriad Genetics' (MYGN) total revenue climbed 8.4% year over year to $188.8 million, beating the Zacks Consensus Estimate of $187 million by a whisker.

Intercept Pharmaceuticals (ICPT) Worth Watching: Stock Gains 16.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 8:25AM CDT
Intercept Pharmaceuticals (ICPT) was a big mover last session, with shares rising nearly 17% on the day.

Regeneron's Eye Drug Eylea Cleared in the EU for DME - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 4:20PM CDT
Regeneron's (REGN) Eylea has been approved for a third indication in the EU.

Sarepta Therapeutics Reports Wider Y/Y Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 1:49PM CDT
Sarepta reported second quarter loss of 85 cents per share compared to a loss of 60 cents per share in the year-ago quarter.

MannKind Posts Wider Q2 Loss, Up on Sanofi Deal for Afrezza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 10:05AM CDT
MannKind's (MNKD) loss of 19 cents per share was wider than the Zacks Consensus Estimate of a loss of 11 cents

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

El Pollo Loco Faces Class Action Over Wage Practices

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Luvme Hair Offers Wig Variety for Winter Fashion

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...